Pegozafermin is a recombinant protein commercialized by 89bio, with a leading Phase III program in Fibrosis. According to Globaldata, it is involved in 8 clinical trials, of which 5 were completed, and 3 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Pegozafermin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Pegozafermin is expected to reach an annual total of $703 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Pegozafermin Overview
pegozafermin (BIO89-100) is under development for the treatment of non-alcoholic steatohepatitis (NASH), liver cirrhosis, fibrosis and severe hypertriglyceridemia. It is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analog. The drug candidate acts by targeting FGF21R (composed of co-receptors FGFR1c, 2c and 3c and KLB). It is administered subcutaneously. It is developed based on glycopegylation technology to prolong the half-life of FGF21.
Pegozafermin was under development for the treatment of non-alcoholic fatty liver disease.
89bio Overview
89bio is a clinical-stage biopharmaceutical company. It primarily focuses on the development and delivery of innovative therapies. The company’s therapies are specifically designed to treat patients suffering from liver and cardiometabolic diseases. 89bio’s lead candidate is pegozafermin (BIO89-100), an investigational glycopegylated FGF21 analog, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Its products are aimed at patients with liver and cardiometabolic diseases, such as MASH and SHTG. It operate offices in Israel and the US. 89bio is headquartered in San Francisco, California, the US.
The operating loss of the company was US$152.4 million in FY2023, compared to an operating loss of US$102.3 million in FY2022. The net loss of the company was US$142.2 million in FY2023, compared to a net loss of US$102 million in FY2022.
For a complete picture of Pegozafermin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
